Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 9

Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis

Authors Medic G, Higashi K, Littlewood KJ, Diez T, Granström O, Kahn RS

Published Date January 2013 Volume 2013:9 Pages 119—131

DOI http://dx.doi.org/10.2147/NDT.S39303

Received 18 October 2012, Accepted 20 November 2012, Published 16 January 2013

Goran Medic,1 Kyoko Higashi,1 Kavi J Littlewood,1 Teresa Diez,2 Ola Granström,3 René S Kahn4

1MAPI Consultancy, Houten, The Netherlands; 2AstraZeneca, Zaventem, Belgium; 3AstraZeneca, Södertälje, Sweden; 4Division of Neuroscience at the Utrecht University Medical Center, Utrecht, The Netherlands

Background: The purpose of this study was to investigate the impact of dosing frequency on adherence in severe chronic psychiatric and neurological diseases.
Methods: A systematic literature review was conducted for articles in English from medical databases. Diseases were schizophrenia, psychosis, epilepsy, bipolar disorder, and major depressive disorder.
Results: Of 1420 abstracts screened, 12 studies were included. Adherence measures included Medication Event Monitoring System (MEMS®), medication possession ratio, medication persistence, and refill adherence. Three schizophrenia and one epilepsy study used MEMS, and all showed a trend towards higher adherence rates with less frequent dosing regimens. Three depression and one schizophrenia study used the medication possession ratio; the pooled odds ratio of being adherent was 89% higher (ie, 1.89, 95% credibility limits 1.71–2.09) on once-daily versus twice-daily dosing. Two studies in depression and one in all bupropion patients assessed medication persistence and refill adherence. The pooled odds ratio for the two depression studies using medication persistence was 2.10 (95% credibility limits 1.86–2.37) for once-daily versus twice-daily dosing. For refill adherence after 9 months, 65%–75% of patients on once-daily versus 56% on twice-daily dosing had at least one refill. In all but one of the studies using other measures of adherence, adherence rates were higher with once-daily dosing compared with more frequent dosing regimens. No relevant studies were identified for bipolar disorder or psychosis.
Conclusion: Differences in study design and adherence measures used across the studies were too large to allow pooling of all results. Despite these differences, there was a consistent trend of better adherence with less frequent dosing.

Keywords: adherence, dosing frequency, schizophrenia, epilepsy, depression

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Decreased white matter integrity before the onset of delusions in patients with Alzheimer's disease: diffusion tensor imaging

Nakaaki S, Sato J, Torii K, Oka M, Negi A, Nakamae T, Narumoto J, Miyata J, Furukawa TA, Mimura M

Neuropsychiatric Disease and Treatment 2013, 9:25-29

Published Date: 27 December 2012

A review of the potential therapeutic role of statins in the treatment of Alzheimer’s disease: current research and opinion

Sánchez-Ferro A, Benito-León J, Mitchell AJ, Bermejo-Pareja F

Neuropsychiatric Disease and Treatment 2013, 9:55-63

Published Date: 4 January 2013

Capgras-like syndrome in a patient with an acute urinary tract infection

Salviati M, Bersani FS, Macrì F, Fojanesi M, Minichino A, Gallo M, De Michele F, Delle Chiaie R, Biondi M

Neuropsychiatric Disease and Treatment 2013, 9:139-142

Published Date: 17 January 2013

General versus executive cognitive ability in pupils with ADHD and with milder attention problems

Ek U, Westerlund J, Fernell E

Neuropsychiatric Disease and Treatment 2013, 9:163-168

Published Date: 29 January 2013

A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice

Bodén R, Edman G, Reutfors J, Östenson CG, Ösby U

Neuropsychiatric Disease and Treatment 2013, 9:371-377

Published Date: 19 March 2013

Maturation of the adolescent brain

Arain M, Haque M, Johal L, Mathur P, Nel W, Rais A, Sandhu R, Sharma S

Neuropsychiatric Disease and Treatment 2013, 9:449-461

Published Date: 3 April 2013

Preventive treatment in migraine and the new US guidelines

Estemalik E, Tepper S

Neuropsychiatric Disease and Treatment 2013, 9:709-720

Published Date: 17 May 2013